Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims match the provided OPVEE label (indication, intranasal use, repeat dosing interval, emergency assistance/continued surveillance, and overdose manifestations). Minor alignment gaps include an imprecise statement about dosing being based on age and first dose, and an inaccurate characterization of dosing as not weight-based (label provides age cut-off but does not address weight-based dosing).
Category Scores
Accurate Statements
Opvee is nalmefene.
Drug description provided in label excerpt (OPVEE nalmefene nasal spray); Section 12.1 mechanism references OPVEE as nalmefene antagonist at opioid receptors.
Opvee is used to reverse opioid overdose.
Section 1 indicates emergency treatment of known or suspected opioid overdose; Section 12.2 describes nalmefene reverses effects of natural and synthetic opioids including respiratory depression and sedation.
For opioid overdose, the typical adult dosing is a single 2.7 mg intranasal spray given as one dose.
Section 2.2: initial dose is one spray delivered by intranasal administration delivering 2.7 mg nalmefene in adults and pediatric patients aged 12 years and older.
If the person does not respond as expected after the initial dose, an additional Opvee dose may be given after 2 to 5 minutes.
Section 2.2: if desired response not obtained after 2 to 5 minutes, administer an additional dose.
If there is no adequate response after the first intranasal dose, Opvee dosing can be repeated every 2 to 5 minutes.
Section 2.2 and Section 2.1: re-administer every 2 to 5 minutes if patient does not respond or responds and then relapses; additional doses every 2 to 5 minutes until emergency assistance arrives if still no response and additional doses are available.
Clinicians monitor even after reversal because opioid effects can wear off and return.
Section 2.1: keep patient under continued surveillance until emergency personnel arrive; Section 5.1: recurrence of respiratory/CNS depression is possible even after adequate initial response.
Opvee is used when opioid overdose is suspected, including slow or stopped breathing or severe sedation/unresponsiveness.
Section 1: manifested by respiratory and/or central nervous system depression; label context supports detection of respiratory depression and CNS depression in overdose.
Opvee dosage is continued every 2 to 5 minutes until emergency help takes over.
Section 2.1/2.2: administer additional doses every 2 to 5 minutes using a new device with each dose until emergency medical assistance arrives.
Children and adults generally follow the same intranasal dose approach.
Section 2.2 specifies dosing for adults and pediatric patients aged 12 years and older (same initial dose and repeat approach described for both groups within that age bracket).
Unsupported Statements
The Opvee dosage is based on the patient’s age and whether this is the first dose.
Label supports an age criterion (adults and pediatric patients aged 12 years and older) and that there is an initial dose, but it does not state that dosing is determined by whether it is the 'first dose' (it states initial dosing and repeat dosing after 2 to 5 minutes if no response/relapse and depends on amount/type/route of opioid being antagonized).
Opvee dosing is determined by an age/weight group and is not “weight-based” in the same way as some other medicines.
Provided label excerpt does not describe any 'weight group' concept or any discussion comparing weight-based dosing to other medicines; it only provides an age threshold (12 years and older) for the indicated use.
Opvee doses may be continued every 2 to 5 minutes until emergency help takes over.
The label supports continuing repeat doses every 2 to 5 minutes until emergency medical assistance arrives, but does not use the phrase 'emergency help takes over' (minor wording difference).
Contradictions
Important Omissions
Seek emergency medical assistance as soon as possible after the first dose and keep the patient under continued surveillance until emergency personnel arrive (explicit instruction present in label but not clearly stated as a separate step in the provided claims list).
Importance:
Moderate
Opvee is intranasal use only (do not prime/test; do not reuse; use new device for each dose).
Importance:
Moderate
Risk of precipitation of severe opioid withdrawal in opioid-dependent patients (signs/symptoms) was not addressed in the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most dosing and repeat-interval information aligns with the label and includes monitoring for recurrence. However, omission of explicit emergency-assistance and continued-surveillance instructions, intranasal/use-only and new-device instructions, and severe opioid withdrawal risk could reduce labeling completeness, which is important for safe administration.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
An inaccurate/unsupported characterization of dosing being based on 'age and whether this is the first dose' and an unsupported claim about 'age/weight group' and not being weight-based.
Suggested Improvement
Rephrase dosing rationale to match label language: initial dose is one 2.7 mg spray for adults and pediatric patients aged 12+; repeat dosing every 2–5 minutes depends on response/relapse and the amount/type/route of the opioid; add explicit instructions to seek emergency medical assistance after the first dose, keep continued surveillance, use intranasal-only administration, and use a new device for each dose; consider including the warning about precipitating severe opioid withdrawal in opioid-dependent patients.